The National Multiple Sclerosis Society has announced Katerina Akassoglou, Ph.D., a leading researcher at the Gladstone Institute of Neurological Disease and the Department of Neurology at the University of California, San Francisco, as the winner of the 2018 Barancik Prize for Innovation in MS Research.
Prof. Akassoglou has led a series of studies to uncover the role of a blood-clotting protein called fibrin, which “leaks” from the damaged blood-brain barrier and gets deposited in MS brain lesions. Her team showed that fibrin deposits hinder natural nervous system repair and can activate immune cells in the brain known as microglia, triggering inflammation and nerve damage. Using an antibody that inhibits fibrin, her team has been able to decrease the activation of microglia, and reduce subsequent damage to nerve fibers in mice.
“I’m humbled and deeply honored to win the Barancik Prize and truly grateful to the committee for recognizing the innovation and translational potential of our work,” said Akassoglou. “I study how leakage of blood damages the brain. Our findings shed new light on mechanisms of brain damage in MS, and introduced novel imaging technologies to study the interactions between the brain, immune system, and the vasculature. Translating findings into treatments is a cornerstone of our research program, and we are committed to developing new therapies for MS.”
Prof. Akassoglou is now developing experimental therapies designed to prevent fibrin from causing damage without affecting its usefulness in blood clotting. She is co-founder of the biotech company MedaRed, Inc., which recently received research funding from the National MS Society through its Fast Forward program to further develop and “humanize” an antibody that targets fibrin, to make it more similar to human antibodies and more suitable for use as a potential therapeutic strategy in people with MS. Targeting fibrin has the potential to protect the nervous system in both early and late phases of MS, of particular importance to people living with MS disability and progression.
“While others dismissed the idea that blood factors could be involved in the nervous system damage in MS, Dr. Akassoglou saw this as an important clue and has relentlessly pursued the idea and is now using this knowledge to translate her discoveries into possible therapies for MS,” said Bruce Bebo, Ph.D., Executive Vice President at the National MS Society, which administers the award. “Her tireless pursuit of a fundamental question in MS and the tenacity to translate this knowledge into potential therapies is why she is being recognized with this year’s Barancik Prize.”
Prof. Akassoglou earned a doctorate in neuroimmunology from the University of Athens, Greece, trained in neuropathology at the University of Vienna and and did postdoctoral work at The Rockefeller University and New York University. Her awards are numerous, including 2007 Presidential Early Career Award for Scientists and Engineers, the John J. Abel Award in Pharmacology, a EUREKA R01, and the NINDS R35 Research Program Award. She has been at the forefront of efforts to facilitate the work of women in MS research.
Prof. Akassouglou will receive the award and deliver the Prize lecture at next month’s ACTRIMS Forum.

The fourth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2019 will take place February 28 – March 2 at the Hilton Anatole in Dallas, Texas.

Themed “Precision Medicine Approaches for MS: Scientific Principles to Clinical Application,” this CME accredited meeting stands apart from many traditional medical meetings by offering a singular track of scientific and clinical presentations in an interactive environment, as well as numerous networking opportunities. Highlights of the Forum include the Kenneth P. Johnson Memorial Lecture and the National Multiple Sclerosis Society (NMSS) Barancik Award presentation and talk. In addition, two poster sessions will showcase approximately 200 posters.

ACTRIMS is committed to fostering the careers of Young Investigators with an interest in MS. The first session of the Forum is composed of platform presentations by Young Investigators who will be selected based on a review of the submitted abstracts. In addition, junior faculty, fellows and students who submit abstracts are eligible for an education grant to support their attendance. Neurologists in training will learn about career paths in clinical and investigative neuroimmunology through the pre-conference event, “Neurology Resident Summit in Multiple Sclerosis.”

ACTRIMS Forum 2019 will provide an excellent opportunity to interact with scientists and clinicians at the cutting edge of MS research. The inaugural ACTRIMS Forum, held in New Orleans in February 2016, was a great success with over 600 participants, well surpassing the original projected attendance of 250. Year after year, the ACTRIMS Forum continues to have record-breaking participation with nearly 1,000 attendees in 2018. Approximately 1,100 attendees are expected in 2019 as ACTRIMS continues to further its mission of providing leadership in the field of multiple sclerosis and other demyelinating diseases.

For more information visit ACTRIMS